

# Frederick W Miller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8536970/publications.pdf>

Version: 2024-02-01

244  
papers

17,392  
citations

11608

70  
h-index

16605

123  
g-index

251  
all docs

251  
docs citations

251  
times ranked

10175  
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Approach to the Classification of Idiopathic Inflammatory Myopathy. <i>Medicine (United States)</i> , 1991, 70, 360-374.	0.4	889
2	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1955-1964.	0.5	754
3	Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. <i>Genome Research</i> , 2010, 20, 170-179.	2.4	569
4	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-controlled phase trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 314-324.	6.7	514
5	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 252-266.	2.0	445
6	A novel autoantibody to a 155-kd protein is associated with dermatomyositis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3682-3689.	6.7	418
7	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , 2017, 69, 2271-2282.	2.9	391
8	Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. <i>Arthritis and Rheumatism</i> , 2012, 64, 2319-2327.	6.7	338
9	Controlled Trial of Plasma Exchange and Leukapheresis in Polymyositis and Dermatomyositis. <i>New England Journal of Medicine</i> , 1992, 326, 1380-1384.	13.9	320
10	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (CHAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle T. <i>Arthritis Care and Research</i> , 2011, 63, S118-57.	1.5	288
11	Epidemiology of environmental exposures and human autoimmune diseases: Findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. <i>Journal of Autoimmunity</i> , 2012, 39, 259-271.	3.0	288
12	Antibody to signal recognition particle in polymyositis. <i>Arthritis and Rheumatism</i> , 1990, 33, 1361-1370.	6.7	283
13	Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. <i>American Journal of Medicine</i> , 1993, 94, 379-387.	0.6	283
14	Current Concepts in the Idiopathic Inflammatory Myopathies: Polymyositis, Dermatomyositis, and Related Disorders. <i>Annals of Internal Medicine</i> , 1989, 111, 143.	2.0	279
15	Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review. <i>Autoimmunity Reviews</i> , 2014, 13, 367-371.	2.5	233
16	Classification criteria for the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 1997, 9, 527-535.	2.0	227
17	The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. <i>Medicine (United States)</i> , 2013, 92, 223-243.	0.4	224
18	Idiopathic inflammatory myopathies. <i>Nature Reviews Disease Primers</i> , 2021, 7, 86.	18.1	212

#	ARTICLE	IF	CITATIONS
19	Predictors of Clinical Improvement in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. <i>Arthritis and Rheumatology</i> , 2014, 66, 740-749.	2.9	210
20	Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. <i>Arthritis Care and Research</i> , 2010, 62, 465-472.	1.5	204
21	International consensus on preliminary definitions of improvement in adult and juvenile myositis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2281-2290.	6.7	202
22	Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2004, 50, 1595-1603.	6.7	195
23	Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. <i>Lancet, The</i> , 2000, 356, 2155-2156.	6.3	173
24	Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells. <i>American Journal of Human Genetics</i> , 2012, 90, 217-228.	2.6	168
25	Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. <i>Arthritis and Rheumatism</i> , 2003, 48, 2285-2293.	6.7	167
26	Treatment of refractory myositis: A randomized crossover study of two new cytotoxic regimens. <i>Arthritis and Rheumatism</i> , 1998, 41, 392-399.	6.7	166
27	Myositis: Immunologic Contributions to Understanding Cause, Pathogenesis, and Therapy. <i>Annals of Internal Medicine</i> , 1995, 122, 715.	2.0	150
28	International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2005, 52, 2607-2615.	6.7	146
29	The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. <i>Medicine (United States)</i> , 2013, 92, 25-41.	0.4	145
30	Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. <i>Lancet, The</i> , 1992, 339, 1192-1195.	6.3	140
31	Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies. <i>Medicine (United States)</i> , 2006, 85, 111-127.	0.4	140
32	Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity. <i>Medicine (United States)</i> , 2008, 87, 70-86.	0.4	137
33	Occupational exposures and autoimmune diseases. <i>International Immunopharmacology</i> , 2002, 2, 303-313.	1.7	135
34	Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 1997, 40, 1257-1266.	6.7	135
35	Diagnosis and classification of idiopathic inflammatory myopathies. <i>Journal of Internal Medicine</i> , 2016, 280, 39-51.	2.7	134
36	Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: Implications for diagnosis and therapy. <i>Arthritis and Rheumatism</i> , 2000, 43, 1866-1873.	6.7	132

#	ARTICLE	IF	CITATIONS
37	Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi2 autoantibodies in women. <i>Arthritis and Rheumatism</i> , 2009, 60, 2499-2504.	6.7	130
38	CLASSIFICATION AND TREATMENT OF THE JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHIES. <i>Rheumatic Disease Clinics of North America</i> , 1997, 23, 619-655.	0.8	128
39	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments. <i>Arthritis and Rheumatism</i> , 1997, 40, 1976-1983.	6.7	127
40	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1558-1566.	0.5	127
41	Defining Clinical Improvement in Adult and Juvenile Myositis. <i>Journal of Rheumatology</i> , 2003, 30, 603-17.	1.0	124
42	Deciphering the Clinical Presentations, Pathogenesis, and Treatment of the Idiopathic Inflammatory Myopathies. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 183.	3.8	115
43	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , 2017, 3, e000507.	1.8	115
44	Identification of distinctive interferon gene signatures in different types of myositis. <i>Neurology</i> , 2019, 93, e1193-e1204.	1.5	115
45	Criteria for environmentally associated autoimmune diseases. <i>Journal of Autoimmunity</i> , 2012, 39, 253-258.	3.0	113
46	Genome-Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. <i>Arthritis and Rheumatism</i> , 2013, 65, 3239-3247.	6.7	113
47	Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1987, 30, 1124-1130.	6.7	108
48	Risk factors and disease mechanisms in myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 255-268.	3.5	108
49	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. <i>Arthritis and Rheumatism</i> , 2009, 60, 3425-3435.	6.7	107
50	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. <i>Genes and Immunity</i> , 2015, 16, 470-480.	2.2	103
51	The Treatment of Inclusion Body Myositis. <i>Medicine (United States)</i> , 1993, 72, 225-235.	0.4	101
52	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014, 69, 436-444.	2.7	100
53	Expert Panel Workshop Consensus Statement on the Role of the Environment in the Development of Autoimmune Disease. <i>International Journal of Molecular Sciences</i> , 2014, 15, 14269-14297.	1.8	100
54	Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 988-995.	0.5	99

#	ARTICLE	IF	CITATIONS
55	Antibodies to glycylâ€‘transfer rna synthetase in patients with myositis and interstitial lung disease. Arthritis and Rheumatism, 1992, 35, 821-830.	6.7	98
56	Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with antiâ€‘Joâ€‘1 and antiâ€‘signal recognition particle autoantibodies. Arthritis and Rheumatism, 1991, 34, 1391-1396.	6.7	97
57	A broadened spectrum of juvenile myositis. myositis-specific autoantibodies in children. Arthritis and Rheumatism, 1994, 37, 1534-1538.	6.7	96
58	Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies. Medicine (United States), 2005, 84, 338-349.	0.4	92
59	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. Annals of the Rheumatic Diseases, 2017, 76, 792-801.	0.5	92
60	Inhibitor of NF-Î² Kinases Î± and Î² Are Both Essential for High Mobility Group Box 1-Mediated Chemotaxis. Journal of Immunology, 2010, 184, 4497-4509.	0.4	90
61	Update on the genetics of the idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2000, 12, 482-491.	2.0	86
62	Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: Ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis and Rheumatism, 2002, 46, 1885-1893.	6.7	86
63	Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis and Rheumatism, 1998, 41, 400-405.	6.7	84
64	Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis and Rheumatism, 2000, 43, 243.	6.7	82
65	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.5	81
66	Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 58, 3941-3950.	6.7	80
67	Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Annals of the Rheumatic Diseases, 2020, 79, 1234-1242.	0.5	80
68	Myositis-Specific Autoantibodies. JAMA - Journal of the American Medical Association, 1993, 270, 1846.	3.8	79
69	HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis and Rheumatism, 2006, 54, 3670-3681.	6.7	78
70	Mechanisms of Disease: environmental factors in the pathogenesis of rheumatic disease. Nature Clinical Practice Rheumatology, 2007, 3, 172-180.	3.2	72
71	Association of Antiâ€‘3â€‘Hydroxyâ€‘3â€‘Methylglutarylâ€‘Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. Arthritis Care and Research, 2017, 69, 1088-1094.	1.5	71
72	Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clinical and Experimental Immunology, 2000, 121, 47-52.	1.1	69

#	ARTICLE	IF	CITATIONS
73	Endothelial cell activation and neovascularization are prominent in dermatomyositis. <i>Journal of Autoimmune Diseases</i> , 2006, 3, 2.	1.0	69
74	Early Illness Features Associated With Mortality in the Juvenile Idiopathic Inflammatory Myopathies. <i>Arthritis Care and Research</i> , 2014, 66, 732-740.	1.5	68
75	Diagnostic criteria for polymyositis and dermatomyositis. <i>Lancet</i> , The, 2003, 362, 1762-1763.	6.3	67
76	Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. <i>Arthritis and Rheumatism</i> , 2006, 54, 3979-3987.	6.7	66
77	Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. <i>Arthritis and Rheumatism</i> , 1998, 41, 710-719.	6.7	65
78	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. <i>JCI Insight</i> , 2020, 5, .	2.3	65
79	Post-epidemic eosinophilia-“myalgia syndrome associated with L-tryptophan. <i>Arthritis and Rheumatism</i> , 2011, 63, 3633-3639.	6.7	61
80	The Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth: The SEARCH Case-Control Study. <i>Diabetes Care</i> , 2017, 40, 46-53.	4.3	61
81	Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. <i>Arthritis and Rheumatism</i> , 2005, 52, 2433-2438.	6.7	60
82	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 911-923.	2.9	59
83	Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American Whites: A tale of two loci. <i>Arthritis and Rheumatism</i> , 1999, 42, 1285-1290.	6.7	58
84	Brief Report: Ultraviolet Radiation Exposure Is Associated With Clinical and Autoantibody Phenotypes in Juvenile Myositis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1934-1941.	6.7	58
85	Chronic Beryllium Disease-“From the Workplace to Cellular Immunology, Molecular Immunogenetics, and Back. <i>Clinical Immunology and Immunopathology</i> , 1994, 71, 123-129.	2.1	57
86	New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, i82-i85.	0.5	57
87	Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. <i>Arthritis and Rheumatism</i> , 2007, 56, 2719-2728.	6.7	55
88	Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. <i>Arthritis and Rheumatism</i> , 2007, 57, 881-884.	6.7	55
89	UV Radiation Regulates Mi-2 through Protein Translation and Stability. <i>Journal of Biological Chemistry</i> , 2008, 283, 34976-34982.	1.6	54
90	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	2.9	52

#	ARTICLE	IF	CITATIONS
91	Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis. <i>Arthritis and Rheumatism</i> , 2008, 59, 214-221.	6.7	51
92	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 782-791.	0.5	51
93	A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 858-864.	1.6	49
94	Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2020-2027.	0.4	48
95	Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. <i>Open Rheumatology Journal</i> , 2012, 6, 54-63.	0.1	48
96	Characterization of human colonic mucoprotein antigen. <i>Immunochemistry</i> , 1974, 11, 369-375.	1.3	47
97	Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. <i>Arthritis Research and Therapy</i> , 2006, 8, R39.	1.6	47
98	Environmental factors associated with disease flare in juvenile and adult dermatomyositis. <i>Rheumatology</i> , 2017, 56, 1342-1347.	0.9	46
99	Idiopathic Inflammatory Myopathies. , 2008, , 368-374.		45
100	HLA type and immune response to <i>Borrelia burgdorferi</i> outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. <i>Arthritis and Rheumatism</i> , 2009, 60, 1179-1186.	6.7	44
101	Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2010, 49, 2381-2390.	0.9	44
102	Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2008, 58, 3239-3246.	6.7	43
103	Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. <i>Arthritis and Rheumatology</i> , 2016, 68, 761-768.	2.9	43
104	Novel gastrointestinal tract manifestations in juvenile dermatomyositis. <i>Journal of Pediatrics</i> , 1999, 135, 371-374.	0.9	42
105	Idiopathic inflammatory muscle disease: clinical aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2000, 14, 37-54.	1.4	42
106	Accommodating Measurements Below a Limit of Detection: A Novel Application of Cox Regression. <i>American Journal of Epidemiology</i> , 2014, 179, 1018-1024.	1.6	42
107	The $\hat{\alpha}^2$ T-Cell Receptor Repertoire in Inclusion Body Myositis: Diverse Patterns of Gene Expression by Muscle-infiltrating Lymphocytes. <i>Journal of Autoimmunity</i> , 1994, 7, 321-333.	3.0	41
108	Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. <i>Arthritis and Rheumatism</i> , 2004, 51, 365-370.	6.7	41

#	ARTICLE	IF	CITATIONS
109	Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 350-356.	0.5	41
110	Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2016, 55, kev344.	0.9	41
111	CLASSIFICATION AND PROGNOSIS OF INFLAMMATORY MUSCLE DISEASE. <i>Rheumatic Disease Clinics of North America</i> , 1994, 20, 811-826.	0.8	41
112	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. <i>Rheumatology</i> , 2022, 61, SI143-SI150.	0.9	40
113	Possible roles and determinants of microchimerism in autoimmune and other disorders. <i>Autoimmunity Reviews</i> , 2004, 3, 454-463.	2.5	39
114	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. <i>Arthritis Research and Therapy</i> , 2020, 22, 69.	1.6	39
115	Viral and host genetic factors influence encephalomyocarditis virus-induced polymyositis in adult mice. <i>Arthritis and Rheumatism</i> , 1987, 30, 549-556.	6.7	38
116	HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. <i>Arthritis and Rheumatism</i> , 2003, 48, 2567-2572.	6.7	37
117	Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: Results using abbreviated formats. <i>Arthritis and Rheumatism</i> , 2008, 59, 352-356.	6.7	37
118	Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. <i>Arthritis Research and Therapy</i> , 2011, 13, R69.	1.6	37
119	Noninfectious environmental agents associated with myopathies. <i>Current Opinion in Rheumatology</i> , 1993, 5, 712-718.	2.0	36
120	Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2009, 11, R159.	1.6	36
121	Environmental Agents and Autoimmune Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2011, 711, 61-81.	0.8	36
122	Gene copy-number variations (CNVs) of complement <i>C4</i> and <i>C4A</i> deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1599-1606.	0.5	36
123	The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 504-512.	1.6	36
124	Mass Spectrometric Determination of IgG Subclass-Specific Glycosylation Profiles in Siblings Discordant for Myositis Syndromes. <i>Journal of Proteome Research</i> , 2011, 10, 2969-2978.	1.8	35
125	Chemical and immunological differences between normal and tumoral colonic mucoprotein antigen. <i>Nature</i> , 1975, 255, 85-87.	13.7	34
126	An enzyme-linked immunosorbent assay for the detection and quantitation of anti-Jo-1 antibody in human serum. <i>Journal of Immunological Methods</i> , 1987, 98, 243-248.	0.6	33



#	ARTICLE	IF	CITATIONS
127	Virus-mediated autoimmunity in Multiple Sclerosis. <i>Journal of Autoimmune Diseases</i> , 2006, 3, 1.	1.0	33
128	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects. <i>Rheumatology</i> , 2017, 56, 1884-1893.	0.9	33
129	Predictors of Reduced Health-Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies. <i>Arthritis Care and Research</i> , 2017, 69, 1743-1750.	1.5	32
130	The Neuromuscular Pathology of the Eosinophilia-Myalgia Syndrome. <i>Journal of Neuropathology and Experimental Neurology</i> , 1991, 50, 49-62.	0.9	31
131	State of the art. <i>Current Opinion in Rheumatology</i> , 2011, 23, 585-594.	2.0	31
132	Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 714-719.	0.5	31
133	Familial autoimmunity and the idiopathic inflammatory myopathies. <i>Current Rheumatology Reports</i> , 2000, 2, 201-211.	2.1	30
134	SERUM-DERIVED IMMUNOSUPPRESSIVE SUBSTANCES. <i>Transplantation</i> , 1976, 21, 179-187.	0.5	29
135	The Immunopathophysiological Effects of Chronic Serum Sickness on Rat Choroid Plexus, Ciliary Process and Renal Glomeruli. <i>Journal of Neuropathology and Experimental Neurology</i> , 1977, 36, 726-733.	0.9	29
136	The Role of Genetic Factors in Autoimmune Disease: Implications for Environmental Research. <i>Environmental Health Perspectives</i> , 1999, 107, 693.	2.8	29
137	Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 1991, 3, 902-910.	2.0	27
138	Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. <i>Arthritis and Rheumatism</i> , 2004, 50, 3646-3650.	6.7	27
139	Metabolic Abnormalities and Cardiovascular Risk Factors in Children with Myositis. <i>Journal of Pediatrics</i> , 2009, 155, 882-887.	0.9	27
140	Reproductive and Hormonal Risk Factors for Antinuclear Antibodies (ANA) in a Representative Sample of U.S. Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2492-2502.	1.1	27
141	Associations Between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999–2004. <i>Environmental Health Perspectives</i> , 2016, 124, 426-436.	2.8	27
142	Glycopeptides of human immunoglobulins—III. <i>Immunochemistry</i> , 1972, 9, 217-228.	1.3	26
143	Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. <i>Rheumatology</i> , 2021, 60, 1839-1849.	0.9	25
144	Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. <i>Rheumatology</i> , 2018, 57, 1956-1963.	0.9	24

#	ARTICLE	IF	CITATIONS
145	Juvenile Dermatomyositis. , 2016, , 351-383.e18.		22
146	Preliminary evidence for the structure of the concanavalin-A binding site on human lymphocytes that induces mitogenesis. Cellular Immunology, 1973, 6, 132-139.	1.4	21
147	Induction of bone by xenografts of rabbit growth plate chondrocytes in the nude mouse. Calcified Tissue International, 1985, 37, 250-256.	1.5	21
148	Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy. Arthritis Care and Research, 2013, 65, 1969-1975.	1.5	21
149	Long-term outcomes in Juvenile Myositis patients. Seminars in Arthritis and Rheumatism, 2020, 50, 149-155.	1.6	21
150	Genetic risk and protective factors for the idiopathic inflammatory myopathies. Current Rheumatology Reports, 2009, 11, 287-294.	2.1	19
151	Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. Arthritis Care and Research, 2020, 72, 1636-1644.	1.5	19
152	A Mucoprotein with Colon-specific Determinants. Tissue Antigens, 1978, 11, 362-371.	1.0	18
153	Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia myalgia syndrome and associated symptoms. Arthritis and Rheumatism, 2009, 61, 1305-1311.	6.7	18
154	Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC Musculoskeletal Disorders, 2014, 15, 67.	0.8	18
155	<italic>N</italic>, <italic>N</italic>-Dimethylformamide-Induced Modulation of Organ- and Tumor-Associated Markers in Cultured Human Colon Carcinoma Cells<xref ref-type="fn" rid="FN2">2</xref> <xref ref-type="fn" rid="FN3">3</xref>. Journal of the National Cancer Institute, 1980, . . .	3.0	17
156	Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. Journal of Rheumatology, 2020, 47, 1011-1018.	1.0	17
157	Simultaneous onset of systemic sclerosis (scleroderma) and lung cancer: A case report and histologic analysis of fibrogenic peptides. American Journal of Medicine, 1992, 92, 705-708.	0.6	16
158	Myositis registries and biorepositories. Current Opinion in Rheumatology, 2014, 26, 724-741.	2.0	16
159	Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases. PLoS ONE, 2015, 10, e0142486.	1.1	16
160	Medications received by patients with juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 48, 513-522.	1.6	16
161	Polymyositis/dermatomyositis associated with dermatitis herpetiformis. Arthritis and Rheumatism, 1989, 32, 1179-1181.	6.7	15
162	Autoantibodies as Predictive and Diagnostic Markers of Idiopathic Inflammatory Myopathies. Autoimmunity, 2004, 37, 291-294.	1.2	15

#	ARTICLE	IF	CITATIONS
163	Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960–2014. <i>PLoS ONE</i> , 2020, 15, e0226516.	1.1	15
164	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. <i>Arthritis and Rheumatology</i> , 2014, 66, S70-S71.	2.9	14
165	Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. <i>Clinical Rheumatology</i> , 2021, 40, 4095-4100.	1.0	14
166	Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 689-96.	0.4	14
167	Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases*. <i>Arthritis Research and Therapy</i> , 2011, 13, R181.	1.6	13
168	Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. <i>Scientific Reports</i> , 2020, 10, 4462.	1.6	13
169	HLA-DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization. <i>Scientific Reports</i> , 2021, 11, 2599.	1.6	13
170	Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. <i>Dermatology Online Journal</i> , 2009, 15, 1.	0.2	13
171	Glycopeptides of human immunoglobulins <sup>1</sup> I preparation and carbohydrate composition. <i>Immunochemistry</i> , 1970, 7, 423-436.	1.3	12
172	Application of immunologic probes for contractile proteins to tissue sections. <i>Clinical Immunology and Immunopathology</i> , 1976, 5, 416-428.	2.1	12
173	Disaccharidase values in iron-deficient infants. <i>Journal of Pediatrics</i> , 1981, 99, 605-608.	0.9	12
174	T cell-mediated immune mechanisms in myositis. <i>Current Opinion in Rheumatology</i> , 1995, 7, 503-509.	2.0	12
175	Focal myositis presenting as pseudothrombophlebitis of the neck in a patient with mixed connective tissue disease. <i>Arthritis and Rheumatism</i> , 1996, 39, 1254-1258.	6.7	12
176	CD3Zhypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3 $\zeta$ -chain expression in T cells. <i>Rheumatology</i> , 2016, 56, kew405.	0.9	12
177	Thyroid Stimulating and Thyrotrophin Binding-Inhibitory Immunoglobulin Activity in Patients with Systemic Lupus Erythematosus Having Thyroid Function Abnormalities. <i>Thyroid</i> , 1991, 1, 229-234.	2.4	11
178	Genetics of Autoimmune Diseases. , 1995, 12, 182-190.		11
179	Genomic organization, transcriptional mapping, and evolutionary implications of the human bi-directional histidyl-tRNA synthetase locus (HARS/HARSL). <i>Biochemical and Biophysical Research Communications</i> , 2002, 294, 609-614.	1.0	11
180	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. <i>Rheumatology</i> , 2016, 55, 1673-1680.	0.9	11

#	ARTICLE	IF	CITATIONS
181	New perspectives on the idiopathic inflammatory myopathies of childhood. <i>Current Opinion in Rheumatology</i> , 1994, 6, 575-582.	2.0	10
182	Prescription medication use and antinuclear antibodies in the United States, 1999–2004. <i>Journal of Autoimmunity</i> , 2018, 92, 93-103.	3.0	10
183	A Biomedical Knowledge Graph System to Propose Mechanistic Hypotheses for Real-World Environmental Health Observations: Cohort Study and Informatics Application. <i>JMIR Medical Informatics</i> , 2021, 9, e26714.	1.3	10
184	Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. <i>Dermatology Online Journal</i> , 2009, 15, 2.	0.2	10
185	Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004). <i>PLoS ONE</i> , 2017, 12, e0185977.	1.1	9
186	Association with HLA-DR <sup>1</sup> position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. <i>Human Molecular Genetics</i> , 2022, 31, 2471-2481.	1.4	9
187	Approaches to risk assessment of immunotoxic effects of chemicals†. <i>Toxicology</i> , 2001, 161, 213-228.	2.0	8
188	<sc>47XXY</sc> and <sc>47XXX</sc> in Scleroderma and Myositis. <i>ACR Open Rheumatology</i> , 2022, 4, 528-533.	0.9	8
189	Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 351-356.	0.4	8
190	Glycopeptides of human immunoglobulins II contribution to the antigenicity of the heavy chain. <i>Immunochemistry</i> , 1971, 8, 99-111.	1.3	7
191	An efficient method for enrichment of histidyl-tRNA synthetase (Jo-1 antigen) from HeLa cells. <i>Journal of Immunological Methods</i> , 1987, 98, 235-241.	0.6	7
192	Transethnic associations among immune-mediated diseases and single-nucleotide polymorphisms of the aryl hydrocarbon response gene ARNT and the PTPN22 immune regulatory gene. <i>Journal of Autoimmunity</i> , 2020, 107, 102363.	3.0	7
193	Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case–control study. <i>Arthritis Research and Therapy</i> , 2007, 9, R95.	1.6	6
194	Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s. <i>Virology Journal</i> , 2011, 8, 450.	1.4	6
195	Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy. <i>Arthritis Research and Therapy</i> , 2015, 17, 238.	1.6	6
196	<sc>Anti-CCortactin</sc> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. <i>Arthritis and Rheumatology</i> , 2022, 74, 358-364.	2.9	6
197	Classification of Idiopathic Inflammatory Myopathies. , 2009, , 15-28.		6
198	Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. <i>Rheumatology</i> , 2022, 61, 2969-2977.	0.9	6

#	ARTICLE	IF	CITATIONS
199	Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). <i>Rheumatology</i> , 2022, 61, S148-S155.	0.9	6
200	Developing international consensus on measures of improvement for patients with myositis. <i>Statistical Methods in Medical Research</i> , 2007, 16, 51-64.	0.7	5
201	Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 1997, 40, 1257-1266.	6.7	4
202	Restricted and Shared Patterns of TCR $\beta$ -chain Gene Expression in Silicone Breast Implant Capsules and Remote Sites of Tissue Inflammation. <i>Journal of Autoimmunity</i> , 2000, 14, 283-293.	3.0	4
203	Hygiene Hypothesis Indicators and Prevalence of Antinuclear Antibodies in US Adolescents. <i>Frontiers in Immunology</i> , 2022, 13, 789379.	2.2	4
204	The Climate Emergency and the Health of Our Patients: The Role of the Rheumatologist. <i>Arthritis and Rheumatology</i> , 2023, 75, 1-3.	2.9	4
205	Serum-Derived Immunosuppressive Substances. <i>International Archives of Allergy and Immunology</i> , 1977, 55, 228-238.	0.9	3
206	Failure of cobra venom factor to inhibit antigen-induced arthritis. <i>Arthritis and Rheumatism</i> , 1977, 20, 1567-1567.	6.7	3
207	Evidence for major differences in ribosomal subunit proteins from <i>Plasmodium berghei</i> and rat liver. <i>Molecular and Biochemical Parasitology</i> , 1984, 12, 249-260.	0.5	3
208	Stimulation and partial stabilization of human histidyl-tRNA synthetase by hemoglobin. <i>FEBS Letters</i> , 1988, 229, 203-205.	1.3	3
209	Idiopathic inflammatory myopathies. <i>Rheumatic Disease Clinics of North America</i> , 2002, 28, xi-xiii.	0.8	3
210	Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: Are current therapies just scratching the surface?. <i>Arthritis and Rheumatism</i> , 2010, 62, 2619-2622.	6.7	3
211	Polymyositis and Dermatomyositis. , 2012, , 1716-1720.		3
212	A58: Demographics, Clinical Features and Therapies of Patients with Juvenile Dermatomyositis Participating in a National Myositis Patient Registry. <i>Arthritis and Rheumatology</i> , 2014, 66, S86-S87.	2.9	3
213	Noninfectious Environmental Agents and Autoimmunity. , 2006, , 297-307.		3
214	Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes. <i>Pediatric Rheumatology</i> , 2022, 20, 28.	0.9	3
215	Expanded assessment of xenobiotic associations with antinuclear antibodies in the United States, 1988-2012. <i>Environment International</i> , 2022, 166, 107376.	4.8	3
216	The effect of specific glycosidase treatment on the responsiveness of lymphocytes. <i>Cellular Immunology</i> , 1974, 10, 136-144.	1.4	2

#	ARTICLE	IF	CITATIONS
217	Serum-Derived Immunosuppressive Substances. International Archives of Allergy and Immunology, 1977, 55, 239-246.	0.9	2
218	Clinical Presentation and Therapy of Idiopathic Inflammatory Myopathies. Journal of Musculoskeletal Pain, 2004, 12, 85-91.	0.3	2
219	Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: Comment on the article by Ruperto et al. Arthritis and Rheumatism, 2008, 59, 1197-1198.	6.7	2
220	Noninfectious Environmental Agents and Autoimmunity. , 2020, , 345-362.		2
221	Post-Zygotic and Inter-Individual Structural Genetic Variation in a Presumptive Enhancer Element of the Locus between the IL10RI <sup>2</sup> and IFNAR1 Genes. PLoS ONE, 2013, 8, e67752.	1.1	2
222	Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2021, 39, 351-356.	0.4	2
223	The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. Frontiers in Medicine, 2022, 9, 842586.	1.2	2
224	Myositis and myopathies. Current Opinion in Rheumatology, 1996, 8, 491-494.	2.0	1
225	Myositis and myopathies. Current Opinion in Rheumatology, 1998, 10, 499-503.	2.0	1
226	Is occupational exposure to mineral oil a risk factor for rheumatoid arthritis?. Nature Clinical Practice Rheumatology, 2006, 2, 130-131.	3.2	1
227	Correction: Inhibitor Of Nk-Î²B Kinases Î± And Î² Are Both Essential for High Mobility Group Box 1-Mediated Chemotaxis. Journal of Immunology, 2010, 184, 7314-7314.	0.4	1
228	Non-infectious Environmental Agents and Autoimmunity. , 2014, , 283-295.		1
229	A25: The Association of Immunogenetic and Environmental Factors with Disease Course in Patients with Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology, 2014, 66, S39-S40.	2.9	1
230	Response to: â€˜Correspondence on â€˜EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsâ€™â€™ by Lrfan<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e41-e41.	0.5	1
231	Slicing and dicing myositis for cures and prevention. Nature Reviews Rheumatology, 2021, 17, 255-256.	3.5	1
232	Molecular Immunology. Volume 11.B. David Hames , David M. Glover. Quarterly Review of Biology, 1997, 72, 507-507.	0.0	1
233	Management of inflammatory muscle disease. , 2015, , 1248-1254.		1
234	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.4	1

#	ARTICLE	IF	CITATIONS
235	Defining anti-synthetase syndrome: a systematic literature review.. Clinical and Experimental Rheumatology, 2022, 40, 309-319.	0.4	1
236	Inflammatory Myopathies. , 2009, , 191-199.		0
237	On Determining the Effects of Therapy on Disease Damage in Non Randomized Studies with Multiple Treatments: A Study of Juvenile Myositis. Communications in Statistics - Theory and Methods, 2009, 38, 3268-3281.	0.6	0
238	Response to: "Comment on: "Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis" by Sabbagh S et al" by Yang et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e97-e97.	0.5	0
239	Signal Recognition Particle Autoantibodies. , 1996, , 735-740.		0
240	Understanding Cancer: From Basic Science to Clinical Practice.Malcolm R. Alison , Catherine E. Sarraf. Quarterly Review of Biology, 1998, 73, 253-253.	0.0	0
241	Annual Review of Immunology. Volume 15: 1997.William E. Paul , C. Garrison Fathman , Henry Metzger. Quarterly Review of Biology, 1998, 73, 254-255.	0.0	0
242	Introduction to Myositis. , 2020, , 1-6.		0
243	Antibodies in Human Diagnosis and Therapy.Edgar Haber , Richard M. Krause. Quarterly Review of Biology, 1978, 53, 81-81.	0.0	0
244	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.4	0